journal article Open Access Jun 01, 2024

Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040

Annals of Oncology Vol. 35 No. 6 pp. 537-548 · Elsevier BV
View at Publisher Save 10.1016/j.annonc.2024.03.005
Topics

No keywords indexed for this article. Browse by subject →

References
43
[1]
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

Hyuna Sung, Jacques Ferlay, Rebecca L. Siegel et al.

CA: A Cancer Journal for Clinicians 2021 10.3322/caac.21660
[2]
Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Hepatocellular Cancers V.2.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed November 10, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
[3]
Evolving therapeutic landscape of advanced hepatocellular carcinoma

Chen Yang, Hailin Zhang, Linmeng Zhang et al.

Nature Reviews Gastroenterology & Hepatology 2023 10.1038/s41575-022-00704-9
[4]
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

Ghassan K. Abou-Alfa, Tim Meyer, Ann-Lii Cheng et al.

New England Journal of Medicine 2018 10.1056/nejmoa1717002
[6]
Zhu J Clin Oncol (2018) 10.1200/jco.2018.36.15_suppl.4003
[7]
El-Khoueiry "Impact of antitumor activity on survival outcomes, and nonconventional benefit, with nivolumab (NIVO) in patients with advanced hepatocellular carcinoma (aHCC): subanalyses of CheckMate-040" J Clin Oncol (2018) 10.1200/jco.2018.36.4_suppl.475
[8]
Meyer (2018)
[9]
Julien "Nivolumab in advanced hepatocellular carcinoma: safety profile and select treatment-related adverse events from the CheckMate 040 study" Oncologist (2020) 10.1634/theoncologist.2019-0591
[10]
Overman "Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer" J Clin Oncol (2018) 10.1200/jco.2017.76.9901
[11]
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

Robert J. Motzer, Nizar M. Tannir, David F. McDermott et al.

New England Journal of Medicine 2018 10.1056/nejmoa1712126
[12]
Hodi "Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial" Lancet Oncol (2016) 10.1016/s1470-2045(16)30366-7
[13]
Yau "Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial" JAMA Oncol (2020) 10.1001/jamaoncol.2020.4564
[14]
(2023)
[15]
(2023)
[16]
Elimova "Updating reports of phase 3 clinical trials for cancer" JAMA Oncol (2021) 10.1001/jamaoncol.2020.6968
[17]
El-Khoueiry "Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (Pts) with advanced hepatocellular carcinoma (aHCC): long-term results from CheckMate 040" J Clin Oncol (2021) 10.1200/jco.2021.39.3_suppl.269
[18]
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E.A. Eisenhauer, P. Therasse, J. Bogaerts et al.

European Journal of Cancer 2009 10.1016/j.ejca.2008.10.026
[19]
Toxicity and response criteria of the Eastern Cooperative Oncology Group

Martin M. Oken, Richard H. Creech, Douglass C. Tormey et al.

American Journal of Clinical Oncology 1982 10.1097/00000421-198212000-00014
[20]
Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

Jedd D. Wolchok, Vanna Chiarion-Sileni, Rene Gonzalez et al.

Journal of Clinical Oncology 2022 10.1200/jco.21.02229
[21]
Paz-Ares "First-line nivolumab plus ipilimumab in advanced NSCLC: 4-year outcomes from the randomized, open-label, phase 3 CheckMate 227 part 1 trial" J Thorac Oncol (2022) 10.1016/j.jtho.2021.09.010
[22]
Motzer "Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma" Cancer (2022) 10.1002/cncr.34180
[23]
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn, Shukui Qin, Masafumi Ikeda et al.

New England Journal of Medicine 2020 10.1056/nejmoa1915745
[24]
Abou-Alfa "Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma" NEJM Evidence (2022) 10.1056/evidoa2100070
[25]
Trojan Nivolumab in sorafenib-naive and -experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040 cohorts 1 and 2. Virtual; Oral presentation at ILCA (2021)
[26]
Kudo "Updated efficacy and safety of KEYNOTE-224: a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib" Eur J Cancer (2022) 10.1016/j.ejca.2022.02.009
[27]
El-Khoueiry "Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial" Lancet (2017) 10.1016/s0140-6736(17)31046-2
[28]
Finn "Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial" J Clin Oncol (2020) 10.1200/jco.19.01307
[29]
Advances in immunotherapy for hepatocellular carcinoma

Bruno Sangro, Pablo Sarobe, Sandra Hervás-Stubbs et al.

Nature Reviews Gastroenterology & Hepatology 2021 10.1038/s41575-021-00438-0
[30]
Roessler "Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior immune checkpoint inhibitor-based combination therapies: a multicenter retrospective study" J Cancer Res Clin Oncol (2023) 10.1007/s00432-022-04206-8
[31]
Wong "Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors" J Immunother Cancer (2021)
[32]
Hwang "Second-line treatment after failure of immune checkpoint inhibitors in hepatocellular carcinoma: tyrosine kinase inhibitor, retrial of immunotherapy, or locoregional therapy?" Liver Cancer (2023)
[33]
Melero "Abstract 2675: Assessment of inflammation biomarkers in relation to clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma in CheckMate 040" Cancer Res (2019) 10.1158/1538-7445.am2019-2675
[34]
Sangro "Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma" J Hepatol (2020) 10.1016/j.jhep.2020.07.026
[35]
Neely "Abstract 2145: Genomic and transcriptomic analyses related to the clinical efficacy of first-line nivolumab in advanced hepatocellular carcinoma from the phase 3 CheckMate 459 trial" Cancer Res (2022) 10.1158/1538-7445.am2022-2145
[36]
Sharma "Anti-CTLA-4 immunotherapy does not deplete FOXP3(+) regulatory T cells (Tregs) in human cancers" Clin Cancer Res (2019) 10.1158/1078-0432.ccr-18-0762
[37]
Ribas "Abstract CT073: Immunomodulatory effects of nivolumab and ipilimumab in combination or nivolumab monotherapy in advanced melanoma patients: CheckMate 038" Cancer Res (2017) 10.1158/1538-7445.am2017-ct073
[38]
Hellmann "Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study" Lancet Oncol (2017) 10.1016/s1470-2045(16)30624-6
[39]
Sznol "Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma" J Clin Oncol (2017) 10.1200/jco.2016.72.1167
[40]
Hammers "Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study" J Clin Oncol (2017) 10.1200/jco.2016.72.1985
[41]
Shitara "Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer" Nature (2022) 10.1038/s41586-022-04508-4
[42]
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma

Yuichiro Doki, Jaffer A. Ajani, Ken Kato et al.

New England Journal of Medicine 2022 10.1056/nejmoa2111380
[43]
Kudo "CheckMate 040 cohort 5: a phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis" J Hepatol (2021) 10.1016/j.jhep.2021.04.047
Cited By
77
Metrics
77
Citations
43
References
Details
Published
Jun 01, 2024
Vol/Issue
35(6)
Pages
537-548
License
View
Cite This Article
I. Melero, T. Yau, Y.-K. Kang, et al. (2024). Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040. Annals of Oncology, 35(6), 537-548. https://doi.org/10.1016/j.annonc.2024.03.005